Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Expert Opin Investig Drugs
; 32(11): 1009-1016, 2023.
Article
em En
| MEDLINE
| ID: mdl-37902056
ABSTRACT
INTRODUCTION:
Geographic atrophy (GA) is a progressive form of age-related macular degeneration (AMD) that leads to severe visual impairment and central vision loss. Traditional treatment options for GA are limited, highlighting the need for new therapeutic approaches. In recent years, targeting the complement system has emerged as a promising strategy for the treatment of GA. AREAS COVERED This expert opinion article reviews the investigational drugs inhibiting the complement cascade for the treatment of GA. Specifically, it focuses on the recent FDA approved pegcetacoplan, a C3 complement inhibitor, and avacincaptad pegol, a C5 complement inhibitor, highlighting their potential efficacy and safety profiles based on clinical trial data. EXPERT OPINION FDA approval of intravitreal pegcetacoplan and avacincaptad pegol marks significant progress in the landscape of GA treatment. However, variable results from trials underscore the complex nature of GA and the importance of patient selection. Complement inhibition holds promise, but ongoing research is vital to refine treatment strategies and offer improved outcomes for GA patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Atrofia Geográfica
/
Degeneração Macular
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article